Antibodies
Antibody Specificity
Antibody Formation
Antibodies, Neutralizing
Antibody Affinity
A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.
Fluorescent Antibody Technique
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
Antibodies, Anti-Idiotypic
Binding Sites, Antibody
Antibodies, Neoplasm
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Neoplasms
Antibodies, Antinuclear
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
Cross Reactions
Neoplasms, Cystic, Mucinous, and Serous
Immunoglobulin M
Autoantibodies
Neutralization Tests
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
Molecular Sequence Data
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Immunohistochemistry
Antigen-Antibody Reactions
Antibodies, Bispecific
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
Single-Chain Antibodies
Amino Acid Sequence
Antibodies, Blocking
Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)
Immunoglobulin G
Antigens, Neoplasm
Antigen-Antibody Complex
Neoplasms, Multiple Primary
Immunoglobulin Fab Fragments
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Antibodies, Heterophile
Antibodies elicited in a different species from which the antigen originated. These antibodies are directed against a wide variety of interspecies-specific antigens, the best known of which are Forssman, Hanganutziu-Deicher (H-D), and Paul-Bunnell (P-B). Incidence of antibodies to these antigens--i.e., the phenomenon of heterophile antibody response--is useful in the serodiagnosis, pathogenesis, and prognosis of infection and latent infectious states as well as in cancer classification.
Antibodies, Catalytic
Immunoenzyme Techniques
Fluorescent Antibody Technique, Indirect
A form of fluorescent antibody technique commonly used to detect serum antibodies and immune complexes in tissues and microorganisms in specimens from patients with infectious diseases. The technique involves formation of an antigen-antibody complex which is labeled with fluorescein-conjugated anti-immunoglobulin antibody. (From Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
Rabbits
Antibodies, Monoclonal, Humanized
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Immunoglobulin A
Hybridomas
Neoplasms, Second Primary
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Immune Sera
Epitope Mapping
Antibodies, Antiphospholipid
Immunization
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Adenocarcinoma, Mucinous
Neoplasms, Experimental
Myeloproliferative Disorders
Ovarian Neoplasms
Antigens, Surface
Blotting, Western
Enzyme-Linked Immunosorbent Assay
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Neoplasm Proteins
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Immunization, Passive
B-Lymphocytes
Cystadenoma
Immunoassay
Neoplasms, Connective and Soft Tissue
Immunoglobulin Fragments
Immunoblotting
Neoplasms, Plasma Cell
Cells, Cultured
Gastrointestinal Neoplasms
Base Sequence
Radioimmunoassay
Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.
Cystadenoma, Mucinous
Sensitivity and Specificity
Electrophoresis, Polyacrylamide Gel
T-Lymphocytes
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Dog Diseases
Carcinoma, Pancreatic Ductal
Flow Cytometry
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Immunologic Techniques
Tumor Markers, Biological
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Complement Fixation Tests
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
Immunoglobulin Variable Region
That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.
Neoplasms, Vascular Tissue
Hemagglutination Tests
Hemagglutination Inhibition Tests
Antibodies, Antineutrophil Cytoplasmic
Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for GRANULOMATOSIS WITH POLYANGIITIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA.
Seroepidemiologic Studies
Neoplasms, Glandular and Epithelial
Testicular Neoplasms
Carcinoma, Papillary
Immunoglobulin Idiotypes
Unique genetically-controlled determinants present on ANTIBODIES whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the IMMUNOGLOBULIN VARIABLE REGION of both immunoglobin polypeptide chains.
Adenocarcinoma, Papillary
Neoplasms, Radiation-Induced
Neoplasm Staging
Hematologic Neoplasms
Immunoglobulins
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
Immunosorbent Techniques
Cattle
Neoplasms, Muscle Tissue
Haptens
Cystadenocarcinoma, Mucinous
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Soft Tissue Neoplasms
Mice, Inbred Strains
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Glycoproteins
Antibodies, Monoclonal, Murine-Derived
Antibody Diversity
The phenomenon of immense variability characteristic of ANTIBODIES. It enables the IMMUNE SYSTEM to react specifically against the essentially unlimited kinds of ANTIGENS it encounters. Antibody diversity is accounted for by three main theories: (1) the Germ Line Theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; (2) the Somatic Mutation Theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and (3) the Gene Rearrangement Theory, which holds that antibody diversity is generated by the rearrangement of IMMUNOGLOBULIN VARIABLE REGION gene segments during the differentiation of the ANTIBODY-PRODUCING CELLS.
Peptide Library
Cystadenocarcinoma
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Neoplasm Transplantation
Colorectal Neoplasms
Hepatitis C Antibodies
Isoantibodies
Vascular Neoplasms
Immunoglobulin Isotypes
Tumor Cells, Cultured
Neoplasms, Adnexal and Skin Appendage
Vaccination
Hepatitis B Antibodies
Peptide Fragments
Immunodiffusion
Palatal Neoplasms
Mutation
Binding, Competitive
Species Specificity
The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.
Immunity, Maternally-Acquired
Antigens, CD
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Carcinoma
Complement System Proteins
Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
Lupus Erythematosus, Systemic
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Recombinant Fusion Proteins
Peptides
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
Immunoglobulin Heavy Chains
Iodine Radioisotopes
Immunochemistry
Neoplasm Metastasis
Autoantigens
Heart Neoplasms
Cystadenoma, Serous
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Bone Marrow Neoplasms
Precipitin Tests
Polymerase Chain Reaction
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Microscopy, Electron
Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen.
Antigens, Protozoan
Tissue Distribution
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
RNA, Messenger
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Membrane Proteins
Neoplasms, Germ Cell and Embryonal
Cloning, Molecular
Antibody-Dependent Cell Cytotoxicity
The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
Disease Models, Animal
Meningeal Neoplasms
Dogs
Autoimmune Diseases
Protein Binding
Retrospective Studies
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Neoplasms, Adipose Tissue
Single-Domain Antibodies
Chromatography, Affinity
Lymphocytes
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Immune responses to all ErbB family receptors detectable in serum of cancer patients. (1/1721)
Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity against all four ErbB receptors among 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2 followed by EGFR, ErbB3 and ErbB4. Specificity patterns comprised tumor patients with unique serum reactivity against ErbB2 or ErbB4. Moreover, approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2 and ErbB3. Serum reactivity was confirmed for the respective ErbB receptors expressed by human tumor cells and corroborated on receptor-specific immunoprecipitates. Positive sera contained ErbB-specific antibodies of the IgG isotype. Representative immunohistochemical analysis of tumor tissues suggested overexpression of ErbB receptors for which serum antibodies were detectable in five of six patients. These findings implicate multiple ErbB receptors including ErbB3 and ErbB4 in addition to EGFR and ErbB2 in primary human cancer. Heterogeneity of natural ErbB-specific responses in cancer patients warrants their evaluation in light of immunotherapeutic approaches targeting these receptors. (+info)Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. (2/1721)
p53 alterations are considered to be predictive of poor prognosis in hepatocellular carcinoma (HCC) and may induce a humoral response. Anti-p53 serum antibodies were assessed by enzyme-linked immunosorbent assay (ELISA) using purified recombinant human p53 on 130 European HCC patients before treatment and during the clinical course of the disease. p53 immunohistochemistry was performed on tumours from the 52 patients who underwent surgery, and DNA sequencing analysis was initiated when circulating anti-p53 antibodies were detected. Nine (7%) HCC patients had anti-p53 serum antibodies before treatment. During a mean period of 30 months of follow-up, all the negative patients remained negative, even when recurrence was observed. Of the nine positive patients, eight were still positive 12-30 months after surgery. The presence of anti-p53 serum antibodies was correlated neither with mutation of the p53 gene nor the serum alpha-fetoprotein levels and clinicopathological characteristics of the tumours. However, a greater incidence of vascular invasion and accumulation of p53 protein were observed in the tumours of these patients (P<0.03 and P<0.01 respectively) as well as a better survival rate without recurrence (P = 0.05). In conclusion, as was recently shown in pancreatic cancer, anti-p53 serum antibodies may constitute a marker of relative 'good prognosis' in a subgroup of patients exhibiting one or several markers traditionally thought to be of bad prognosis. (+info)Identification of the human melanoma-associated chondroitin sulfate proteoglycan antigen epitope recognized by the antitumor monoclonal antibody 763.74 from a peptide phage library. (3/1721)
To identify the epitope of the melanoma-associated chondroitin sulfate proteoglycan (MCSP) recognized by the monoclonal antibody (mAb) 763.74, we first expressed random DNA fragments obtained from the complete coding sequence of the MCSP core glycoproteins in phages and selected without success for binders to the murine mAb 763.74. We then used a library of random heptapeptides displayed at the surface of the filamentous M13 phage as fusion protein to the NH2-terminal portion of the minor coat protein III. After three rounds of selection on the bound mAb, several phages displaying related binding peptides were identified, yielding the consensus sequence Val-His-Leu-Asn-Tyr-Glu-His. Competitive ELISA experiments showed that this peptide can be specifically prevented from binding to mAb 763.74 by an anti-idiotypic MK2-23 mouse:human chimeric mAb and by A375 melanoma cells expressing the antigen MCSP. We screened the amino acid sequence of the MCSP molecule for a region of homology to the consensus sequence and found that the amino acid sequence Val-His-Ile-Asn-Ala-His spanning positions 289 and 294 has high homology. Synthetic linear peptides corresponding to the consensus sequence as well as to the MCSP-derived epitope inhibit the binding of mAb 763.74 to the phages displaying the consensus amino acid sequence. Finally, the biotinylated consensus peptide absorbed to streptavidin-microtiter plates can be used for the detection of mAb 763.74 in human serum. These results show clearly that the MCSP epitope defined by mAb 763.74 has been identified. (+info)A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa. (4/1721)
In this study we performed N-terminal sequence analysis of gp20, a 20 kDa sialoglycoprotein on the human sperm surface previously identified by radiolabelling of the sialic acid residues of sperm surface. We found 100% identity with the N-terminus of CD52, an antigen expressed on almost all human leukocytes. We also show that, like CD52, gp20 behaves as a glycosylphosphatidylinositol (GPI)-anchored protein and that anti-gp20 antiserum reacts with an antigen on leukocytes of the same molecular weight as CD52. Using CAMPATH-1, the monoclonal antibody against CD52, in fluorescent staining of capacitated spermatozoa, Western blot analysis and the zona-free hamster egg penetration test, we found that the effect of this antibody was different from that of our anti-gp20. Western blot analysis revealed a well-defined 20 kDa band with anti-gp20, whereas a 14-20 kDa band was detected with CAMPATH-1. Anti-gp20 stained the equatorial region of the sperm head, whereas CAMPATH-1 stained the tail in immunofluorescence analysis of capacitated spermatozoa. A dose-dependent inhibitory effect was seen with CAMPATH-1, similar to that previously detected with anti-gp20, in a zona-free hamster egg penetration test. However, with CAMPATH-1 agglutination of motile spermatozoa was detected, and this was not present with anti-gp20. This suggests that the epitopes recognized by the two antibodies are different. (+info)Adoptive immunotherapy of a Gross virus producing lymphoma and a methylcholanthrene-induced fibrosarcoma in tolerant rats. (5/1721)
Immunological tolerance to Gross virus-specific transplantation antigens in rats given neonatae transfer of donor lymphoid cells beneath the kidney capsule of syngeneic recipient rats. Immune or normal donor cells invariably developed a cell-mediated immune reaction in kidneys of GV-tolerant recipients, presumably against GV antigens present on the surface of recipient lymphoid cells in the kidney. Spleen and lymph node cells from tolerant rats failed to develop a reaction in tolerant recipients, but developed a strong reaction to histoincompatible antigens in the kidneys of semisyngeneic tolerant rats. The immunologically tolerant state in the rats could be broken by adoptive transfer of spleen and lymph node cells from syngeneic rats immunized with GV-induced lymphoma cells. Immunotherapy of a GV-induced and also a GV-infected methylcholanthrene-induced fibrosarcoma growing in tolerant rats was successful when immune spleen and lymph node cells were administered i.p. 3 days after s.c. inoculation of 2 X 10(7) tumor cells in the case of the lymphoma, and 1 day after inoculation of 5 X 10(6) tumor cells in the case of the fibrosarcoma. (+info)Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. (6/1721)
PURPOSE: BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately eight doxorubicin molecules. The antibody is directed against the Lewis-Y antigen, which is expressed on 75% of all breast cancers but is limited in expression on normal tissues. Preclinical xenograft models demonstrated significant antitumor activity, including cures. A randomized phase II design was chosen to estimate the activity of the BR96-doxorubicin conjugate in metastatic breast cancer in a study population with confirmed sensitivity to single-agent doxorubicin. PATIENTS AND METHODS: Patients with measurable metastatic breast cancer and immunohistochemical evidence of Lewis-Y expression on their tumor received either BR96-doxorubicin conjugate 700 mg/m2 IV over 24 hours or doxorubicin 60 mg/m2 every 3 weeks. Patients were stratified on the basis of prior doxorubicin exposure, visceral disease, and institution. Cross-over to the opposite treatment arm was allowed with progressive or persistently stable disease. RESULTS: Twenty-three patients who had received a median of one prior chemotherapy regimen were assessable. There was one partial response (7%) in 14 patients receiving the BR96-doxorubicin conjugate and one complete response and three partial responses (44%) in nine assessable patients receiving doxorubicin. No patient experienced a clinically significant hypersensitivity reaction. The toxicities were significantly different between the two treatment groups, with the BR96-doxorubicin conjugate group having limited hematologic toxicity, whereas gastrointestinal toxicities, including marked serum amylase and lipase elevations, nausea, and vomiting with gastritis, were prominent. CONCLUSION: The BR96-doxorubicin immunoconjugate has limited clinical antitumor activity in metastatic breast cancer. The gastrointestinal toxicities likely represent binding of the agent to normal tissues expressing the target antigen and may have compromised the delivery of the immunoconjugate to the tumor sites. (+info)Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. (7/1721)
PURPOSE: In patients undergoing cytokine therapy, systemically applied interleukin-2 (IL-2) and/or interferon-alpha (IFN-alpha) have been reported to induce thyroid dysfunction as well as thyroid autoantibodies. We analyzed the correlation of thyroid autoimmunity with HLA phenotype, various other autoimmune parameters, and patient survival. PATIENTS AND METHODS: For this purpose, antithyroglobulin autoantibodies, antimicrosomal thyroid autoantibodies, thyroglobulin receptor autoantibodies, thyroid dysfunction, and multiple clinical parameters were determined in 329 unselected patients with metastatic renal cell cancer before and after systemic IL-2 and IFN-alpha2 therapy. For statistical analysis, we used both univariate and multivariate Cox proportional hazards models and the two-tailed Fisher's exact test. RESULTS: Antithyroglobulin autoantibodies and antimicrosomal thyroid autoantibodies were detected in 60 patients (18%); positive autoantibody titers of various other autoimmune parameters were statistically unrelated. The presence of thyroid autoantibodies was correlated with prolonged survival (P<.0001). There was a statistically significant difference in frequencies of HLA-Cw7 expression between thyroid autoantibody-positive and -negative patients (P< or =.05), and the Cw7 expression was associated with prolonged overall survival (P = .009). CONCLUSION: The evaluation of thyroid autoantibodies during cytokine therapy could be a useful prognostic marker for patients with renal cell carcinoma who benefit from cytokine treatment. IL-2- and IFN-alpha2-induced tumor control and prolonged survival may require breaking of immunologic tolerance against self-antigens. (+info)Prognostic value of p53 genetic changes in colorectal cancer. (8/1721)
PURPOSE: To explore whether there is a linkage between different mutations in the p53 gene in primary colorectal cancer and the risk of death from colorectal cancer in a large group of patients with long follow-up. We also compared a complementary DNA-based sequencing method and an immunohistochemical (IHC) method for detecting p53 protein overexpression in colorectal cancer. MATERIALS AND METHODS: The entire coding region of the p53 gene was sequenced in 191 frozen tumor samples collected from January 1988 to November 1992. RNA was extracted and synthesized to cDNA. p53 was amplified by the polymerase chain reaction, and the DO-7 monoclonal antibody was used in the IHC assessments. RESULTS: Mutations were detected in 99 samples (52%) from 189 patients. There was a significant relationship between the p53 mutational status and the cancer-specific survival time, with shorter survival time for patients who had p53 mutations than for those who did not (P = .01, log-rank test). Mutations outside the evolutionarily conserved regions were associated with the worst prognosis. Multivariate analysis showed that the presence of p53 mutations was an independent prognostic factor (relative hazard, 1.7, P = .03). There was no significant relationship between overexpression of p53 protein, as determined by IHC analysis, and cancer-specific survival. CONCLUSION: Mutational analyses of the p53 gene, using cDNA sequencing in colorectal cancer, provide useful prognostic information. In addition, cDNA sequencing gives better prognostic information than IHC assessment of p53 protein overexpression. (+info)
Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and...
Antigens recognized by autologous antibody in patients with renal-cell carcinoma
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One - Full Text View - ClinicalTrials.gov
Alemtuzumab : usage, side effects, expert advice and alemtuzumab based medicines | 1mg
Alemtuzumab B-Cell Proliferation May Create New Autoimmunities in MS
CAMPATH (Alemtuzumab) dosage, indication, interactions, side effects | EMPR
I received alemtuzumab CARE MS II extension study
Anti-CD13 antibody [CC81] (ab36439) | Abcam
Anti-WC1 antibody [CC101] (ab34050) | Abcam
anti-CD1w3 antibody [CC43] | GeneTex
anti-Wc1 antibody [CC15] (FITC) | GeneTex
RCSB PDB
- 1AD9: IGG-FAB FRAGMENT OF ENGINEERED HUMAN MONOCLONAL ANTIBODY CTM01 Literature Report Page
Campath worked great for me for 6 months, then RELAPSE CITY
Tips for Care Partners | LEMTRADA® (alemtuzumab)
Anti-p38抗体[M138] (ab31828)参考文献| Abcam中国官方网站
p107抗体|Abcam中国|Anti-p107抗体(ab90507)
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a...
Typhlitis as a complication of alemtuzumab therapy | Haematologica
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL -...
Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses | JEM
I 131 monoclonal antibody CC49 | Chemwatch
Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte...
Immunological studies on mouse mammary tumors. Iii. Surface antigens by K Nishioka, R F. Irie et al.
mutations of mortality: April 2008
Alemtuzumab - Monoclonal Antibody Used in the Treatment of Leukemia and Lymphoma Hematology
Současné možnosti využítí monoklonálních protilátek v protinádorové léčbě | proLékaře.cz
Drug safety evaluation of alemtuzumab for multiple sclerosis -ORCA
Multiple Sclerosis Research: CAM-THY a new alemtuzumab (campath-1h) trial
Patient Guide. Important information for patients starting therapy with LEMTRADA (alemtuzumab) - PDF Free Download
Campath Maintenance in Chronic Lymphocytic Leukemia
Anti-CD4 [YNB46.1.8 (Campath-9H)]
Search for Alemtuzumab
AANAM - Lemtrada Fares Well in Preliminary Studies for RRMS
https://www.medicalnewstoday.com/releases/317890.php
Lemtrada
Lemtrada
Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for...
Molecular cloning of a monoclonal anti-tumor antibody specific for the Tn antigen and expression of an active single-chain Fv...
CAMPATH-1 monoclonal antibodies in bone marrow transplantation. - Oxford Neuroscience
Subcutaneous Alemtuzumab May Be Useful in the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. | Blood |...
Seminars - [April 25. 2019] Colorful World of Quantum Dots
IJMS | Free Full-Text | Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
Cancer Care Nova Scotia - Drug Monograph for ALEMTUZUMAB
Anti CD52 (Alemtuzumab Biosimilar) Antibody, clone Campath-1H | Bio-Rad
Treatment-Naive Patients with Highly Active RRMS Demonstrated Durable Efficacy with Alemtuzumab over 5 Years (S51.003) |...
Alemtuzumab Controlled Clinical and MRI Outcomes and Slowed Brain Volume Loss in RRMS Patients: 8-Year Follow-up of CARE-MS II...
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following...
MSCOVID19 Its not T-time is M-time. Alemtuzumab shows more evidence to support a major role for the macrophage - Multiple...
Routine Clinical Use of Alemtuzumab in Patients With Heavily Pretreated B-cell Chronic Lymphocytic Leukemia: A Nation-Wide...
Anti-CD4 (Campath-9H), Rabbit IgG, kappa Antibody | A2012 | BioVision, Inc.
DMOZ - Health: Pharmacy: Drugs and Medications: A: Alemtuzumab
Multiple Sclerosis Research: Alemtuzumab kills B cells. Not Really a Stepford Wife
Multiple Sclerosis Research: Alemtuzumab kills B cells. Not Really a Stepford Wife
Multiple Sclerosis Research: Alemtuzumab kills B cells. Not Really a Stepford Wife
Relapsing MS Infusion Treatment | LEMTRADA® (alemtuzumab)
The CAMPATH-1 antigen (CDw52). - Oxford Neuroscience
Lemtrada - Uses, Side Effects, Interactions - Drug Factsheets - C-Health
Anti-MUC1 抗体 [EPR1023] (ab109185) | アブカム
Anti-p27 KIP 1 抗体 [EPFHCR16] (ab92741) | アブカム
Cathepsin K
"Anti-Cathepsin K Antibody (A5871)". Antibodies.com online catalog. Antibodies.com Ltd. 2018. Retrieved 16 January 2018. Brömme ... 1 February 2013). "A Broad Survey of Cathepsin K Immunoreactivity in Human Neoplasms". American Journal of Clinical Pathology. ... Cathepsin K antibodies are marketed for research into expression of this enzyme by various cells. Merck had a cathepsin K ... "Cathepsin K Antibodies". Novus Biologicals online catalog. Novus Biologicals, LLC. 2016. Retrieved 2 October 2016. "Anti- ...
Thyroid
The most common neoplasm affecting the thyroid gland is a benign adenoma, usually presenting as a painless mass in the neck. ... These antibodies activate the receptor, leading to development of a goitre and symptoms of hyperthyroidism, such as heat ... Lastly, antibodies against components of the thyroid, particularly anti-TPO and anti-thyroglobulin, can be measured. These may ... Occasionally such antibodies block but do not activate the receptor, leading to symptoms associated with hypothyroidism. In ...
Monoclonal antibody therapy
Initial research on malignant neoplasms found mAb therapy of limited and generally short-lived success with blood malignancies ... Antibody-drug conjugates (ADCs) are antibodies linked to one or more drug molecules. Typically when the ADC meets the target ... Four major antibody types that have been developed are murine, chimeric, humanised and human. Antibodies of each type are ... Initial therapeutic antibodies were murine analogues (suffix -omab). These antibodies have: a short half-life in vivo (due to ...
A20 cells
AT20 cells are BALB/c lymphoma cells derived from spontaneous reticulum cell neoplasm. ATCC TIB-208 cells originated from B- ... A20 cells are also highly responsive to immunomodulatory antibodies, and are therefore used frequently in immunotherapy drug ...
Mycoplasma genitalium
The antibody reactivity was due to a protein never known before, and is chemically responsive to all types of human and ... The protein was identified during investigations on the origin of multiple myeloma, a B-cell hematologic neoplasm. To ... "A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union". Science. 343 (6171): 656-661 ... nonhuman antibodies available. The protein is about 50 kDa in size, and composed of 556 amino acids. Tully, J. G.; Taylor- ...
Monoclonality
Monoclonal neoplasm (tumor): A single aberrant cell which has undergone carcinogenesis reproduces itself into a cancerous mass ... Common usages of this term include: Monoclonal antibody: A single hybridoma cell, which by chance includes the appropriate V(D) ... In informal laboratory jargon, the monoclonal antibodies isolated from cell culture supernatants of these hybridoma clones ( ... J recombination to produce the desired antibody, is cloned to produce a large population of identical cells. ...
CD79
... serves to be a pan-B cell marker for the detection of B-cell neoplasms. However, tumor cells in some cases of T- ... "Anti-CD79 antibody induces B cell anergy that protects against autoimmunity". Journal of Immunology. 192 (4): 1641-50. doi: ... Other studies that focused on the deficiencies observed in neonatal antibody production can be due to various intrinsic ... lymphoblastic leukemia/lymphoma and AML has shown to potentially react positively with CD79 monoclonal antibodies. In addition ...
Plasma cell
These antibodies are transported from the plasma cells by the blood plasma and the lymphatic system to the site of the target ... and plasma cell leukemia are malignant neoplasms ("cancer") of the plasma cells. Multiple myeloma is frequently identified ... LLPC can maintain antibody production for decades or even for the lifetime of an individual, and, unlike B cells, LLPC do not ... Plasmablasts secrete more antibodies than B cells, but less than plasma cells. They divide rapidly and are still capable of ...
Proliferating cell nuclear antigen
... or monoclonal antibody termed Ki-67 can be used for grading of different neoplasms, e.g. astrocytoma. They can be of diagnostic ... PCNA type 1 and type 2 Antibody Patterns". Antibody Patterns.com. Retrieved 2008-04-15. Dan Krotz. "Structure of a clamp-loader ... Imaging of the nuclear distribution of PCNA (via antibody labeling) can be used to distinguish between early, mid and late S ... However, an important limitation of antibodies is that cells need to be fixed leading to potential artifacts. On the other hand ...
Lymphoid neoplasms with plasmablastic differentiation
... the plasmablasts in lymphoid neoplasms with plasmablastic differentiation do not mature into plasma cells or form antibodies ... Lymphoid neoplasms with plasmablastic differentiation were classified by the World Health Organization, 2017 as a sub-grouping ... In cases so infected, the lymphoid neoplasm may result, at least in part, from this viral infection and therefore can be ... The lymphoid neoplasms with plasmacytic differentiation are: 1) Plasmablastic lymphoma: The most common of these lymphoid ...
Lingual tonsils
B lymphocytes kill pathogens by producing antibodies against them, while T lymphocytes directly kill them by engulfing them or ... Squamous cell carcinoma is a type of neoplasm that can affect lingual tonsils. Enlarged or hypertrophic lingual tonsils have ...
Paraneoplastic pemphigus
... intraepidermal antibodies as well as along the dermoepidermal junction. Patients with low concentration of antibodies only ... in association with an underlying neoplasm". A study concluded in 2009, summarized in 2010, surrounded the surgical removal of ... Demonstration of certain antibodies in the serum was named as the basis for diagnosis of PNP. This piece labeled PNP as a " ... Specifically, antibodies against envoplakin and periplakin were being investigated. Further use of ELISA testing on these ...
Autoimmune autonomic ganglionopathy
Where an underlying neoplasm is the cause, treatment of this condition is indicated in order to reduce progression of symptoms ... If the AAG is paraneoplastic, they have a form of cancer, and their immune system has produced paraneoplastic antibodies in ... Additionally, a blood test showing high levels of the antibody ganglionic nicotenic acetylcholine receptor (gAChr) occur in ... Paola Sandroni & Phillip A. Low (2009). "Other Autonomic Neuropathies Associated with Ganglionic Antibody". Autonomic ...
Brunangelo Falini
Using monoclonal antibodies against ALK and NPM1, Falini and colleagues took major steps forward in the biological and clinical ... Falini also contributed to the development over time of modern classifications of lympho-hematopoietic neoplasms, including ... His scientific activity ranges from the field of monoclonal antibodies for diagnostic and therapeutic purposes to genomic ... Falini was a pioneer in the generation of novel monoclonal antibodies directed against oncoproteins involved in the ...
Pregnancy test
... heterophile antibodies, enterocystoplasties, gestational trophoblastic diseases (GTD), and gestational trophoblastic neoplasms ... In the 1970s, the discovery of monoclonal antibodies led to the development of the relatively simple and cheap immunoassays, ... heterophilic antibody, familial hCG syndrome and cancer. Urine tests can be falsely positive in those that are taking the ... which is due to people having human antianimal or heterophilic antibodies. False positives can also be caused by (in order of ...
List of MeSH codes (D12.776.124)
... antibodies, neoplasm MeSH D12.776.124.486.485.114.248 - antibodies, phospho-specific MeSH D12.776.124.486.485.114.252 - ... antibodies, neoplasm MeSH D12.776.124.790.651.114.248 - antibodies, phospho-specific MeSH D12.776.124.790.651.114.252 - ... antibodies MeSH D12.776.124.486.485.114.071 - antibodies, anti-idiotypic MeSH D12.776.124.486.485.114.089 - antibodies, ... antibodies, bispecific MeSH D12.776.124.486.485.114.143 - antibodies, blocking MeSH D12.776.124.486.485.114.167 - antibodies, ...
Immunoglobulin light chain
Only one type of light chain is present in a typical antibody, thus the two light chains of an individual antibody are ... with a highly divergent ratio indicative of neoplasm. The quotient of kappa divided by lambda, according to a novel polyclonal ... The immunoglobulin light chain is the small polypeptide subunit of an antibody (immunoglobulin). A typical antibody is composed ... Monoclonal antibody Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA (2001). "Serum reference ...
CD44
Monoclonal antibodies against CD44 variants include bivatuzumab for v6. CD44 is a multistructural and multifunctional cell ... On the contrary, in some neoplasms CD44 upregulation is associated with a favorable outcome. This is true of prostate cancer, ... Experiments in animals have shown that targeting of CD44 by antibodies, antisense oligonucleotides, and CD44-soluble proteins ... markedly reduces the malignant activities of various neoplasms, stressing the therapeutic potential of anti-CD44 agents. High ...
Milatuzumab
A Phase I study of Milatuzumab, a humanized anti-CD74 antibody, and Veltuzumab, a humanized anti-CD20 antibody, in patients ... CD74: a new candidate target for the immunotherapy of B-cell neoplasms. R. Stein, M.J. Mattes, T.M. Cardillo, H.J. Hansen, C.H ... Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. P. Sapra, R. Stein, J ... hLL1-Dox Milatuzumab has been linked to doxorubicin to form an antibody-drug conjugate or ADC (known as hLL1-Dox or IMMU-110) ...
Trophoblastic neoplasm
Although chemotherapy and hysterectomy are currently used in a clinical setting, the use of diverse treatments including anti- ...
Clone (cell biology)
Another important area where one can talk of "clones" of cells is neoplasms. Many of the tumors derive from one (sufficiently) ... These terms are most commonly used in context of antibodies or immunocytes. This concept of clone assumes importance as all the ... The B cells in the body have two important phenotypes (functional forms)-the antibody secreting, terminally differentiated ( ... "Clonal origin and expansions in neoplasms: biologic and technical aspects must be considered together". The American Journal of ...
Radioimmunotherapy
By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal ... In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to ... A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer Smith-Jones PM. ... The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells ...
Autoimmune hemolytic anemia
Classification of the antibodies is based on their activity at different temperatures and their etiology. Antibodies with high ... Less common causes of warm-type AIHA include neoplasms other than lymphoid, and infection. Secondary warm type AIHA has been ... Usually, the antibody becomes active when it reaches the limbs, at which point it opsonizes RBCs. When these RBCs return to ... Antibodies are produced against the RBCs, which leads to complement activation. Complement fragments, such as C3a, C4a and C5a ...
YM Biosciences
The company also advanced other clinical-stage products, including Nimotuzumab, an EGFR-targeting monoclonal antibody, and ... which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and ... YM BioSciences' principal medicine of interest was a monoclonal antibody - Nimotuzumab - targeting the epidermal growth factor ...
Francis Peyton Rous
Rous, P. (1909-11-01). "Parabiosis as a test for circulating anti-bodies in cancer: First paper". The Journal of Experimental ... Rous, Peyton (1910-09-01). "A transmissible avian neoplasm.(Sarcoma of the common fowl.)". Journal of Experimental Medicine. 12 ... Noyes, W. F.; Mellors, R. C. (1957-10-01). "Fluorescent antibody detection of the antigens of the Shope papilloma virus in ... that the neoplasm will differ from the better-known tumors of mammals." He continued to maintain and transplant the tumor in ...
NS0 cell
Development of murine neoplasms started with work with the BALB/c mice to isolate the IgG1 secreting MOPC21 tumor. From this ... Several therapeutic antibody products are produced using the NS0 cell line including daclizumab and eculizumab. Barnes, LM; ... Galfrè, G; Milstein, C (1981). "Preparation of monoclonal antibodies: strategies and procedures". Methods in Enzymology. 73 (Pt ... NSo cells are naturally antibody-producing suspension cells with a lymphoblast morphology. Gene amplification is typically ...
Lloyd J. Old
Quantitative analysis of antibody localization in human metastatic colon cancer: A phase I study with monoclonal antibody A33. ... Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 1995;92:11810-11813. ... Of the monoclonal antibodies developed in Dr. Old's laboratory, thirteen have been licensed and seven are in clinical trials. ... the anti-EGFr antibody Hu806, which Abbott Laboratories acquired exclusive world-wide rights to develop in a major licensing ...
Paroxysmal cold hemoglobinuria
Monoclonal antibodies e.g. rituximab (anti-CD20) and eculizumab (anti-C5) have been used but the therapeutic benefits are ... as well as hematological malignancies including non-Hodgkin lymphoma and myeloproliferative neoplasms. The exact pathogenesis ... As a weak, biphasic antibody, it absorbs to the P antigen in the cold temperature as in the periphery in the primary phase, and ... Autoimmune hemolytic anemia Warm-antibody type Primary Secondary (lymphoproliferative disorders, autoimmune disorders): 259 ...
Immunocontraception
All women generated antibodies against hCG, but only 119 (80%) generated antibody titers clearly above 50 ng/mL, which was the ... hCG was discovered to be expressed in certain kinds of malignant neoplasms, including breast cancer, adenocarcinoma of the ... In passive immunity the desired antibody titers are achieved by injecting antibodies directly into an animal. The efficacy of ... anti-sperm antibodies are not likely to have adverse health effects, since anti-sperm antibodies are produced by up to 70% of ...
Index of oncology articles
... monoclonal antibody - monoclonal antibody 3F8 - monocyte - Montanide ISA-51 - Morinda citrifolia - morphology - motexafin ... neoplasm - nephrotomogram - nephrotoxic - nephroureterectomy - nerve block - nerve grafting - nerve-sparing radical ... bispecific antibody - bispecific monoclonal antibody - bisphosphonate - bizelesin - BL22 immunotoxin - black cohosh - black ... antibody - antibody therapy - anticachexia - anticancer antibiotic - anticarcinogenic - anticoagulant - anticonvulsant - ...
Papillary carcinomas of the breast
The World Health Organization (2019) classified papillary neoplasms (i.e. benign or cancerous tumors) of the breast into 5 ... cytokeratin 5/6 antibodies that detect two markers of myoepithelial cells, cytokeratin 5 and keratin 6A); 3) the presence of a ... Brogi E, Krystel-Whittemore M (January 2021). "Papillary neoplasms of the breast including upgrade rates and management of ... Tay TK, Tan PH (June 2021). "Papillary neoplasms of the breast-reviewing the spectrum". Modern Pathology. 34 (6): 1044-1061. ...
List of diseases (C)
Cohen syndrome Colavita-Kozlowski syndrome Cold abscess Cold agglutination syndrome Cold agglutinin disease Cold antibody ... Carrington syndrome Cartilage hair hypoplasia like syndrome Cartilage-hair hypoplasia Cartilaginous neoplasms Cartwright-Nelson ... hypoxia Cerebral malformations hypertrichosis claw hands Cerebral palsy Cerebral thrombosis Cerebral ventricle neoplasms ... Choriocarcinoma Chorioretinitis Chorioretinopathy dominant form microcephaly Choroid plexus cyst Choroid plexus neoplasms ...
Waldenström macroglobulinemia
It is characterized by having high levels of a circulating antibody, immunoglobulin M (IgM), which is made and secreted by the ... ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... Treatment includes the monoclonal antibody rituximab, sometimes in combination with chemotherapeutic drugs such as chlorambucil ... Hematologic malignant neoplasms, Lymphoma, Rare cancers, Vascular-related cutaneous conditions). ...
Index of biochemistry articles
... neoplasm protein - Nernst equation - nerve - nerve growth factor - nerve growth factor receptor - nerve tissue protein - nerve ... antibody - apoenzyme - apolipoprotein - apoptosis - aquaporin - archaea - arginine - argipressin - aromatic amine - aromatic ... monoclonal antibody - monomer - monosaccharide - monosaccharide transport protein - morphogenesis - morphogenetic field - mos ...
Primary effusion lymphoma
The efficacy of rituximab in CD- PEL may be due to the ability of this antibody to kill non-malignant CD+ 20 lymphocytes and ... This lymphoma also belongs to a group of lymphoid neoplasms with plasmablastic differentiation that involve malignant ... Rituximab, a monoclonal antibody directed against and killing CD20-expressing cells, appears to improve the efficacy of ... One factor that appears to improve the treatment of Type II PEL is the addition of rituximab (a monoclonal antibody directed ...
Mature T-cell lymphoma
It has a chimeric monoclonal antibody (cAC10) that binds to the membrane protein CD30. This binding delivers monomethyl ... "The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375-2390. doi: ... "The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications". Blood. 117 (19): ...
CD79A
However, the presence of both the CD79a and CD79b ITAM tyrosines were required for normal T cell dependent antibody responses. ... and is also present in virtually all B-cell neoplasms, including B-cell lymphomas, plasmacytomas, and myelomas. It is also ...
Cancer
They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... Approaches include antibodies, checkpoint therapy, and adoptive cell transfer. Laser therapy uses high-intensity light to treat ...
Ubiquitin
Kales SC, Ryan PE, Nau MM, Lipkowitz S (June 2010). "Cbl and human myeloid neoplasms: the Cbl oncogene comes of age". Cancer ... Immunohistochemistry using antibodies to ubiquitin can identify abnormal accumulations of this protein inside cells, indicating ... "DNA copy number losses in human neoplasms". The American Journal of Pathology. 155 (3): 683-94. doi:10.1016/S0002-9440(10)65166 ...
[email protected]
2006). "Rearrangement of only one human IGHV gene is sufficient to generate a wide repertoire of antigen specific antibody ... IGHV is the immunoglobulin heavy chain variable region genes; in B-cell neoplasms like chronic lymphocytic leukemia, mutations ... "Nucleotidic sequence analysis of the variable domains of four human monoclonal IgM with an antibody activity to myelin- ...
Chronic lymphocytic leukemia
In practice, this is inferred by the detection of only one of the mutually exclusive antibody light chains, kappa or lambda, on ... Hairy cell leukemia is also a neoplasm of B lymphocytes, but the neoplastic cells have a distinct morphology under the ... Normal B lymphocytes consist of a stew of different antibody-producing cells, resulting in a mixture of both kappa- and lambda- ... ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ...
Periodontal disease
Pussinen PJ, Alfthan G, Rissanen H, Reunanen A, Asikainen S, Knekt P (September 2004). "Antibodies to periodontal pathogens and ... induced Genetic/developmental disorders Specific infections Inflammatory and immune conditions Reactive processes Neoplasms ... Pussinen PJ, Alfthan G, Tuomilehto J, Asikainen S, Jousilahti P (October 2004). "High serum antibody levels to Porphyromonas ... suppression of antibody production, and the reduction of phagocytosis by neutrophils Ehlers-Danlos syndrome and Papillon- ...
CYLD cutaneous syndrome
Articles with short description, Short description is different from Wikidata, Epidermal nevi, neoplasms, and cysts, Conditions ... a monoclonal antibody that neutralizes tumor necrosis factor alpha). Both of these individuals showed slowly developing, modest ... Trichofolliculoma Spiradenoma spiradenocarcinoma List of cutaneous conditions List of cutaneous neoplasms associated with ... "Treatment of multiple familial trichoepitheliomas with a combination of aspirin and a neutralizing antibody to tumor necrosis ...
Radiation therapy
Targeting can also be achieved by attaching the radioisotope to another molecule or antibody to guide it to the target tissue. ... Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... which is a combination of an iodine-131 labelled and an unlabelled anti-CD20 monoclonal antibody. These medications were the ... which is an anti-CD20 monoclonal antibody conjugated to yttrium-90. In 2003, the FDA approved the tositumomab/iodine (131I) ...
List of skin conditions
Within this list, the term immunoglobulin is abbreviated to Ig when used as a prefix to a specific antibody isotype (i.e. IgA, ... neoplasms, and cysts are skin lesions that develop from the epidermal layer of the skin. Aberrant basal cell carcinoma ... an overview with emphasis on the myeloid neoplasms". Chem. Biol. Interact. 184 (1-2): 16-20. doi:10.1016/j.cbi.2009.10.009. ... neoplasms invading or aberrantly present in the dermis. Acquired progressive lymphangioma (benign lymphangioendothelioma) Acral ...
Gibbon ape leukemia virus
Furthermore, antibodies against the retrovirus was identified in gibbons without evidence of disease which suggests a natural ... Gibbon-ape leukemia virus (GaLV) is an oncogenic, type C retrovirus that has been isolated from primate neoplasms, including ... Olagoke, O.; Quigley, B. L.; Eiden, M. V.; Timms, P. (2019-08-27). "Antibody response against koala retrovirus (KoRV) in koalas ... The virus was identified as the etiological agent of hematopoietic neoplasms, leukemias, and immune deficiencies within gibbons ...
Plasmacytoid dendritic cell
When DNA is released via apoptosis of an infected host cell, antibodies are produced against the host's own DNA. (see ... Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel ... Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare type of myeloid cancer in which malignant pDCs infiltrate the ... pDCs that undergo malignant transformation cause a rare hematologic disorder, blastic plasmacytoid dendritic cell neoplasm. In ...
Acute lymphoblastic leukemia
The cDNA is sequenced and the sequence encoding the variable heavy and variable light chains of these antibodies are cloned ... May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. ... In this therapy, mice are immunized with the CD19 antigen and produce anti-CD19 antibodies. Hybridomas developed from mouse ... An extensive panel of monoclonal antibodies to cell surface markers, particularly CD or cluster of differentiation markers, are ...
Elaine Jaffe
Jaffe and her fellow NCI researchers showed that red blood cells coated with antibody and erythrocyte-antibody-complement (EAC ... of the Society of Hematopathology at the time that the WHO's Revised European-American Classification of Lymphoid Neoplasms ( ...
History of cancer chemotherapy
"Humanization" of these antibodies (genetically transforming them to be as similar to a human antibody as possible) has allowed ... A study of 93 patients with incurable neoplasms". J Natl Med Assoc. 43 (4): 211-240. PMC 2616951. PMID 14850976. Li, MC; Hertz ... Although monoclonal antibodies (immune proteins which can be selected to precisely bind to almost any target) have been around ... Another branch in targeted therapy is the increasing use of monoclonal antibodies in cancer therapy. ...
PDGFRB
This continuous signaling, it is presumed, leads to the development of myeloid and/or lymphoid neoplasms that commonly include ... For instance, forcing PDGFRβ into close proximity of each other by overexpression or with antibodies directed against the ... PDGFRB-ETV6 fusion protein-induced neoplasms often present with features that would classify them as Chronic myelomonocytic ... These patients, unlike many patients with similarly appearing neoplasms, respond well to the tyrosine kinase inhibitor, ...
MALT lymphoma
Rituximab, the anti-CD20 chimeric antibody, is a key component of therapy. Responses vary from 55% to 77% with monotherapy and ... ISBN 0-7817-5007-5. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ...
Glossary of communication disorders
Laryngeal neoplasms Abnormal growths in the larynx (voice box) that can be cancerous or noncancerous. Laryngeal nodules ... Autoimmune deafness Individual's immune system produces abnormal antibodies that react against the body's healthy tissues. ...
Murine respirovirus
SeV antibodies that cross-reactive with HPIV-1 antibodies are present in most people, however, majority of people do not have ... Its expression is also increased in a wide range of other malignant neoplasms. Factor X (F10) is frequently expressed in normal ... Instead, it can be measured using anti-glycan antibodies, and despite the large collection of such antibodies in a community ... and from antibodies-online.com (No. ABIN6737444) . Monoclonal antibodies (IgG1) to F-protein are available from Kerafast ( ...
Diffuse large B-cell lymphoma associated with chronic inflammation
Rituximab is a commercial monoclonal antibody that binds to the CD20 cell surface protein on B-cells to thereby target these ... An Indolent Neoplasm With Features Distinct From Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation". The ... to immunotherapy with either one of these monoclonal antibodies. A phase I clinical trial is recruiting individuals to study ...
Epithelioid sarcoma
They can also include the administration of laboratory-produced antibodies specific to tumor antigens to create or boost an ... a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study ... Vaccines can deliver various tumor-associated factors (tumor antigens) to the immune system, resulting in a natural antibody ...
Stem cell marker
June 2001). "Expression of anti-OV6 antibody and anti-N-CAM antibody along the biliary line of normal and diseased human livers ... Misago N, Narisawa Y (September 2006). "Cytokeratin 15 expression in neoplasms with sebaceous differentiation". Journal of ... ALDH alkaline phosphatase alpha6-integrin Anti-WNT2B monoclonal antibody antithrombin III (AT) asialo GM1 Bcl-2 Beta- ...
List of MeSH codes (D12.776)
... antibodies, neoplasm MeSH D12.776.377.715.548.114.248 - antibodies, phospho-specific MeSH D12.776.377.715.548.114.252 - ... antibodies MeSH D12.776.377.715.548.114.071 - antibodies, anti-idiotypic MeSH D12.776.377.715.548.114.107 - antibodies, ... antibodies, bispecific MeSH D12.776.377.715.548.114.143 - antibodies, blocking MeSH D12.776.377.715.548.114.167 - antibodies, ... antibodies, helminth MeSH D12.776.377.715.548.114.191 - antibodies, heterophile MeSH D12.776.377.715.548.114.224 - antibodies, ...
Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. - Nuffield Department of...
These 32 individuals and 64 matched controls were analyzed for serum antibodies indicative of past infection with Chlamydia ... antibodies to C. trachomatis showed the strongest association with cervical cancer (odds ratio = 5.0 (95% confidence interval ... Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. ... Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. ...
UCSF Neoplasms Trial → TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With...
This Neoplasms and Solid Tumor study at UCSF is now recruiting people ages 18 years and up. ... Neoplasms, Metastatic solid tumors, Advanced solid tumors, anti-PD-1, TSR-042, Immunotherapy, PD-1, Endometrial, Non-small cell ... A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced ... Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid ...
CK13 in craniopharyngioma versus related odontogenic neoplasms and human enamel organ
The monoclonal antibody NCL-CK13 was studied in specimens of craniopharyngioma, ameloblastoma and calcifying odontogenic cyst ... CK13 in craniopharyngioma versus related odontogenic neoplasms and human enamel organ. dc.contributor.author. El Sissy, N.A.. ... This suggests that these neoplasms might have their histogenesis from early stage epithelium, the oral part of the dental ... The neoplastic epithelia of the neoplasms revealed a clear phenotypic and immunohistochemical reactive relationship to the ...
Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors - Full Text View - ClinicalTrials.gov
Neoplasms Malignant Drug: AK112 Phase 1 Study Design. Go to Top of Page Study Description Study Design Arms and Interventions ... A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors. The safety and scientific validity of this study ... anti-PD-1/VEGF bispecific antibody. immunotherapy. immuno-oncology. advanced solid tumors. bispecific. PD-1/VEGF. ... Number of subjects who develop detectable anti-drug antibodies (ADAs) [ Time Frame: From first dose of AK112 through 90 days ...
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer - Full Text View - ClinicalTrials.gov
Neoplasms by Site. Neoplasms by Histologic Type. Genital Neoplasms, Female. Urogenital Neoplasms. Uterine Neoplasms. Uterine ... Known severe (Grade ≥ 3) hypersensitivity reactions to fully human monoclonal antibodies, antibody, or severe reaction to ... Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer. The safety and scientific validity of this study is the ... Anti-drug Antibodies (ADAs) [ Time Frame: First study dose (pre-dose) through 3 months following last study dose (up to 2 years ...
COVID-19 vaccination in patients with cancer, a rapid review - ecancer
Antibodies, Viral, Antibodies, Neutralizing, COVID-19, SARS Virus, Immunogenicity, Vaccine and Neoplasms. ... 27. Van Oekelen O, Gleason CR, and Agte S, et al (2021) Highly variable SARS-CoV-2 spike antibody responses to two doses of ... 38. Lim SH, Campbell N, and Johnson M, et al (2021) Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma ... 23. Palich R, Veyri M, and Vozy A, et al (2021) High seroconversion rate but low antibody titers after two injections of ...
Cold Agglutinin Disease: Practice Essentials, Pathophysiology, Etiology
Crisp D, Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med. 1982 Jun. 72(6): ... Warm-cold antibody combinations. Hemolysis due to cold agglutinins can sometimes be accompanied by a warm antibody (IgG), ... In mixed antibody syndromes, the IgG and IgM antibody components can be separated. The cold autoantibodies reactive at ... Uncommonly, the antibody may be directed against only the i antigen found on fetal cord blood RBCs, which lack the mature I ...
Progress in Chronic Disease Prevention
Summary of a Workshop on Screening for Hepatocellular Carcinoma
Neoplasms of the liver. New York: Springer-Verlag, 1987:189-97. 10. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, ... Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and cirrhosis. Lancet 1989;2: ... Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-8. 13. ...
Cryptosporidium baileyi Pulmonary Infection in Immunocompetent Woman with Benign Neoplasm - Volume 26, Number 8-August 2020 -...
A BW smear was labeled with genus-specific fluorescein isothiocyanate-conjugated antibodies (indirect fluorescent antibody ... Cryptosporidium baileyi Pulmonary Infection in Immunocompetent Woman with Benign Neoplasm On This Page ... Findings from a 51-year-old immunocompetent woman with a benign neoplasm and Cryptosporidium baileyi pulmonary infection, ... Cryptosporidium baileyi Pulmonary Infection in Immunocompetent Woman with Benign Neoplasm. Emerging Infectious Diseases. 2020; ...
SciELO - Brazil - Are clinicopathological features of the isthmic thyroid nodule different from nodules in thyroid lobes? A...
Anti-TPO: anti-thyroid peroxidase antibody; Anti-Tg: anti-thyroglobulin antibody; TIRADS: Thyroid Imaging Reporting and Data ... follicular neoplasm/suspicious for follicular neoplasm (FN/SFN), suspicious for malignancy and malignant according to Bethesda ... follicular neoplasm/suspicious for follicular neoplasm; PTC: papillary thyroid cancer. ... follicular neoplasm/suspicious for follicular neoplasm; PTC: papillary thyroid cancer ...
A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and...
Neoplasms, Plasma Cell. Smoldering Multiple Myeloma. Neoplasms by Histologic Type. Neoplasms. Hemostatic Disorders. Vascular ... Patients with antiviral therapy for HCV started before initiation of IMP and positive HCV antibodies are eligible. The ... Number of participants with anti-drug antibodies against isatuximab. *Sustained MRD negativity [ Time Frame: Up to ... Immunogenicity: Incidence of anti-drug antibodies (ADA) [ Time Frame: Up to approximately 24 months ]. ...
Non-Hodgkin Lymphoma (NHL) Medication: Cytotoxic agents, Antineoplastic Agents, Histone Deacetylase Inhibitors, Antineoplastics...
In general, lymphomas are divided into 2 large groups of neoplasms, namely non-Hodgkin lymphoma (NHL) and Hodgkin disease. ... Antineoplastics, Anti-CD19 Monoclonal Antibodies. Class Summary. The monoclonal antibody binds to human CD19, a transmembrane ... A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood ... Monoclonal Antibodies. Class Summary. The agents in this class target specific antigens in carcinoma cells and induce ...
Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy |...
Subject: antineoplastic agents / Subject term: antineoplastic activity / Text Availability: Citation in PubAg - PubAg Search...
... fluorescent antibody technique; humans; lung neoplasms; mechanism of action; models; morbidity; phosphorylation; proteome; ... esophageal neoplasms; glutamine; human health; liver neoplasms; neoplasm cells; pH; pancreatic neoplasms; pollution; research; ... antineoplastic activity; antineoplastic agents; biosynthesis; breast neoplasms; colorectal neoplasms; humans; lung neoplasms; ... lung neoplasms; neoplasm cells. Abstract:. ... In this study, a series of novel naphthalimide-benzotriazole conjugates (1a-3c) ...
Dr Shahram Kordasti
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer...
Keith L Knutson - Research output - Mayo Clinic
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected ... of memory precursor cd8 t cells in regressing tumors following combination therapy with vaccine and anti-pd-1 antibody. ... by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody ...
Cold Agglutinin Disease: Practice Essentials, Pathophysiology, Etiology
Crisp D, Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med. 1982 Jun. 72(6): ... Warm-cold antibody combinations. Hemolysis due to cold agglutinins can sometimes be accompanied by a warm antibody (IgG), ... In mixed antibody syndromes, the IgG and IgM antibody components can be separated. The cold autoantibodies reactive at ... Uncommonly, the antibody may be directed against only the i antigen found on fetal cord blood RBCs, which lack the mature I ...
Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative...
A, JAK2 V617F and WT HUVEC lysates were subjected to SDS-PAGE and immunoblotted with anti-JAK2 and anti-GAPDH antibodies. B, ... Myeloproliferative neoplasms (MPN) are disorders of the bone marrow characterized by excess clonal hematopoiesis resulting in ... A, JAK2 V617F and WT HUVEC lysates were subjected to SDS-PAGE and immunoblotted with anti-JAK2 and anti-GAPDH antibodies. B, ... The following antibodies were used: mouse monoclonal anti-PDI (RL77; Abcam Cat#ab5484, RRID:AB_304927), rabbit polyclonal anti- ...
Rob Ainsworth - Research output - University of Edinburgh Research Explorer
Paraneoplastic Myeloneuropathies | Neurology
Among 7 patients, no neoplasms were identified. ANNA1 = antineuronal nuclear antibody type 1 (anti-Hu); ANNA3 = antineuronal ... onconeural antibodies, n = 19; unclassified antibodies, n = 3; no antibodies, n = 3). Paraneoplastic myeloneuropathies had ... microtubule-associated protein 1B antibody; mRS=. modified Rankin Scale; PCA=. Purkinje cell cytoplasmic antibody. ... Figure 1 Cancer and Onconeural Antibody Associations. (A) Summary of onconeural antibodies and presence of cancer; 3 patients ...
WHO EMRO | Chlamydia trachomatis and cervical intraepithelial neoplasia in married women in a Middle Eastern community | Volume...
Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. American journal of ... Serum antibodies to C. trachomatis were associated with an increased risk for CIN [odds ratio (OR) = 7.3; 95% confidence ... Table 1 Association between CIN with the presence of IgG antibodies to Chlamydia trachomatis or inclusion bodies of C. ... The prevalence of serum antibodies positive for C. trachomatis was 22 (41%) for CINI, 3 (100%) for CINII and 2 (66%) for CINIII ...
Suchen nach Schlagwort "Kraniopharyngeom"
DMBT1 expression is down-regulated in breast cancer<...
Neoplasm Antibodies Medicine & Life Sciences 29% * Polymerase Chain Reaction Medicine & Life Sciences 25% ... Methods: Sections from 17 benign lesions and 55 carcinomas were immunostained with anti DMBT1 antibody (DMBTh12) and sections ... Methods: Sections from 17 benign lesions and 55 carcinomas were immunostained with anti DMBT1 antibody (DMBTh12) and sections ... Methods: Sections from 17 benign lesions and 55 carcinomas were immunostained with anti DMBT1 antibody (DMBTh12) and sections ...
Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF®...
Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence ... These neoplasms predominantly had epithelial origin, with overexpressing the Epidermal Growth Factor Receptor (EGFR) in a high ... due to its capacity to develop anti EGF antibodies able to reduce circulating EGF concentrations by increasing the antibody ... Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence, ...
Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on...
... such as B lymphocyte antibody deficiencies, T lymphocyte complete or partial defects, HIV infection, malignant neoplasms, ... or antibody avidity. Studies were excluded if they lacked a comparison group in which efficacy of 3 doses of HPV vaccine ... Because antibody kinetics are similar with 2-dose and 3-dose series, duration of protection is also expected to be long-lasting ...
Bile Duct Neoplasms | Harvard Catalyst Profiles | Harvard Catalyst
MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma. ... "Bile Duct Neoplasms" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... This graph shows the total number of publications written about "Bile Duct Neoplasms" by people in Harvard Catalyst Profiles by ... Below are the most recent publications written about "Bile Duct Neoplasms" by people in Profiles. ...
BCG vaccine
Progress in Chronic Disease Prevention Summary of a Workshop on Scre
Neoplasms of the liver. New York: Springer-Verlag, 1987:189-97. * Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze ... Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and cirrhosis. Lancet 1989;2: ... Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-8. * ...
Monoclonal AntibodyAntigensTumorsFluorescence In Situ HybriProteinsFlow cytometryImmunotherapyAnti EGFR monoclonal antibodiesParaneoplasticIMMUNOHISTOCHEMISTRYAntigenTherapeuticMyeloproliferative neoplasmsMalignant neoplasmMetastaticMurine monoclonalBenignLymphomaProteasome InhibitorsDilutionMultiple myelomaSeroconversionInhibitorsProteinImmunohistochemical evaluationAssaysCancerAutoantibodiesImmuneTumor cellsBiologicalTrachomatisMucinousNeuroendocrineSystemicHumanDyLightSerumPeptidesMalignanciesLesions
Monoclonal Antibody11
- The monoclonal antibody NCL-CK13 was studied in specimens of craniopharyngioma, ameloblastoma and calcifying odontogenic cyst neoplasms and the mandible and maxillae of normal human fetuses. (who.int)
- Campath(®), Genzyme, MA, USA) has recently been investigated in a Phase II clinical trial in the treatment of relapsing-remitting MS. The results observed in the study are very encouraging and multiple insights have been made into the nature of autoimmunity in general based on the clinical response to this monoclonal antibody. (nih.gov)
- Cold agglutinins commonly have variable heavy-chain regions encoded by VH, with a distinct idiotype identified by the 9G4 rat murine monoclonal antibody. (medscape.com)
- Red: PE-labeled Cyclin D1 Monoclonal Antibody (SPM587). (novusbio.com)
- When unlabeled antibody is used the cells are further incubated with a labeled antibody against the monoclonal antibody and the presence of labeled ternary immune complexes on the cells is read. (justia.com)
- As used herein the term "monoclonal antibody" means an antibody composition having a homogeneous antibody population. (justia.com)
- CINQAIR (reslizumab) Injection is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype. (tevausa.com)
- TNFSF14 can be a cytokine neutralization target during novel coronavirus infection, and anti-TNFSF14 monoclonal antibody treatment can reduce the risk of respiratory failure and mortality. (bvsalud.org)
- The prognosis of HER2-positive breast cancer has dramatically improved because of introduction of trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of HER2. (e-crt.org)
- The anti-PD1 monoclonal antibody pembrolizumab improves survival in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). (elsevier.com)
- Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human tumour necrosis factor (TNF).Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. (ecco-ibd.eu)
Antigens3
- Cold agglutinin disease usually results from the production of a specific IgM antibody directed against the I/i antigens (precursors of the ABH and Lewis blood group substances) on red blood cells (RBCs). (medscape.com)
- Since the mid-1970s, there have been numerous reports of murine monoclonal antibodies that interact with human breast cancer associated antigens. (justia.com)
- They can also exhibit antibodies to antigens associated with pemphigus vulgaris (desmoglein 3, 130-kd) and pemphigus foliaceus (desmoglein 1, 160-kd), as well as several others, including epiplakin. (medscape.com)
Tumors5
- This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. (ucsf.edu)
- On the other hand, the CIMAvax EGE vaccine has shown therapeutic efficacy in patients with non-small cell lung tumors (NSCLC) [7], due to its capacity to develop anti EGF antibodies able to reduce circulating EGF concentrations by increasing the antibody titer in treated patients. (scirp.org)
- Primary ovarian mucinous tumors represent a heterogeneous group of neoplasms, and their diagnosis may be challenging. (bvsalud.org)
- KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors. (cdc.gov)
- The antibody in this study binds to certain types of cancer tumors. (survivornet.com)
Fluorescence In Situ Hybri1
- Results consistent with neoplasm may prompt fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) testing for BCR-ABL or Jak 2 . (medscape.com)
Proteins5
- Methods: Sections from 17 benign lesions and 55 carcinomas were immunostained with anti DMBT1 antibody (DMBTh12) and sections from 36 samples, were double-stained also with anti MCM5, one of the 6 pre-replicative complex proteins with cell proliferation-licensing functions. (elsevier.com)
- Proteins were visualized using chemiluminescence detection by incubation with HRP Goat anti-Mouse secondary antibody (Cat. (biolegend.com)
- Dr. Binder studies the epigenetic determinants of gene expression in chronic myeloid neoplasms associated with mutations in the chromatin-remodeling proteins such as ASXL1. (mayo.edu)
- Plasma cells help your body fight infection by producing proteins called antibodies . (medlineplus.gov)
- Antibodies are proteins normally made by the immune system that bind to substances that don't belong in the body to prevent harm. (survivornet.com)
Flow cytometry2
- Flow Cytometry: Cyclin D1 Antibody (SPM587) [NBP2-32840] - Flow Cytometric analysis of human Cyclin D1 on MCF-7 cells. (novusbio.com)
- Flow Cytometry: Cyclin D1 Antibody (SPM587) [NBP2-32840] - Flow Cytometric analysis of human Cyclin D1 on Jurkat cells. (novusbio.com)
Immunotherapy1
- It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity. (fpnotebook.com)
Anti EGFR monoclonal antibodies1
- Although there are reports of some studies with anti EGFR monoclonal antibodies (mAbs) in this indication, in advanced stages, the results have not been as expected. (scirp.org)
Paraneoplastic4
- The clinical presentation that corresponds with PCA-Tr antibodies includes paraneoplastic cerebellar degeneration (PCD) and limbic encephalopathy (LE). (loinc.org)
- Hematologic malignancies are most commonly associated with paraneoplastic pemphigus, although it can also be associated with carcinomas, sarcomas, and benign neoplasms. (medscape.com)
- Paraneoplastic pemphigus is an autoimmune disorder initiated by an underlying neoplasm. (medscape.com)
- Passive transfer of paraneoplastic pemphigus sera causes blistering in neonatal mice, proving that the antibodies present are pathogenic. (medscape.com)
IMMUNOHISTOCHEMISTRY2
- Immunohistochemistry-Paraffin: Cyclin D1 Antibody (SPM587) [NBP2-32840] - Formalin-paraffin human Mantle Cell Lymphoma stained with Cyclin D1 Ab (Clone SPM587). (novusbio.com)
- The immunohistochemistry technique was performed by the streptavidin-biotin method using the antibody anti-MMP9. (bvsalud.org)
Antigen5
- CD45 belongs to a leukocyte common antigen (LCA antibody) family of glycoproteins with molecular weights of 180, 190, 205 and 220 kDa. (biocare.net)
- Leukocyte common antigen-a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections using monoclonal antibodies: correlation with immunologic studies and ultrastructural localization. (biocare.net)
- 4. Negative human immunodeficiency virus (HIV) antibody screen, seronegative for hepatitis B surface antigen (HBsAg) and hepatitis C antibody (following HIV and hepatitis testing, subjects will be provided with counseling and referral for health care if any test is positive). (who.int)
- Using this staining technique, fluorescent dye is attached to the known antibodies that correspond to the suspected antigen, in this case, the leukemia cells. (cdc.gov)
- These antibodies will in turn attach to the antigen molecules on the cell surfaces, and if present, will fluoresce when viewed with a fluorescent light. (cdc.gov)
Therapeutic2
- In collaboration with Mrinal S. Patnaik, M.B.B.S. , he investigates the suitability of cis-regulatory elements to serve as therapeutic targets in high-risk myeloid neoplasms. (mayo.edu)
- More particularly it concerns murine monoclonal anti-human breast cancer antibodies, hybridomas that produce those antibodies, immunochemicals made from those antibodies, and diagnostic and therapeutic methods that use those immunochemicals. (justia.com)
Myeloproliferative neoplasms1
- Thromboembolic events (TE) are the most common complications of myeloproliferative neoplasms (MPN). (aacrjournals.org)
Malignant neoplasm3
- Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence, principally from epithelial origen. (scirp.org)
- Cervical uterine cancer represents the fourth malignant neoplasm with the highest incidence in the world in women with 569,847 in 2018. (scirp.org)
- Those precancerous lesions, according to WHO definition, are morphological lesions, related to increased risk of malignant neoplasm to occur. (hindawi.com)
Metastatic1
- Given these results, the authors discuss the difficulty in diagnosing differentiation from a primary or metastatic neoplasm of the scalp, with the resources currently available, until the conclusion that it was a primary carcinoma of the sweat gland. (bvsalud.org)
Murine monoclonal1
- Murine monoclonal antibodies are prepared and characterized which bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. (justia.com)
Benign1
- Findings from a 51-year-old immunocompetent woman with a benign neoplasm and Cryptosporidium baileyi pulmonary infection, Poland, 2015. (cdc.gov)
Lymphoma2
- Purkinje cell cytoplasmic-Tr (PCA-Tr) antibodies are associated with Hodgkin's lymphoma. (loinc.org)
- As for a new umbrella category of PTCL, nodal peripheral T-cell lymphoma with T-follicular helper phenotype (NPTCL-TFH) was firstly classified in the 2017 revision of the World Health Organization (WHO) classification of hematolymphoid neoplasms. (researchsquare.com)
Proteasome Inhibitors1
- In collaboration with Shaji Kumar, M.D. , he studies the gene expression patterns and chromatin structure of multiple myeloma resistant to immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies. (mayo.edu)
Dilution6
- Immunofluorescence analysis of paraformaldehyde-fixed HeLa, using Fibronectin (GTX112794) antibody at 1:200 dilution. (genetex.com)
- Fibronectin antibody [N1N2], N-term (GTX112794) dilution: 1:500. (genetex.com)
- Various lysates were subjected to SDS PAGE followed by western blot with 17785-1-AP (Synaptophysin antibody) at dilution of 1:40000 incubated at room temperature for 1.5 hours. (ptglab.com)
- Immunohistochemical analysis of paraffin-embedded mouse brain tissue slide using 17785-1-AP (Synaptophysin antibody) at dilution of 1:2000 (under 10x lens). (ptglab.com)
- Immunohistochemical analysis of paraffin-embedded mouse brain tissue slide using 17785-1-AP (Synaptophysin antibody) at dilution of 1:2000 (under 40x lens). (ptglab.com)
- Optimal dilution of this antibody should be experimentally determined. (novusbio.com)
Multiple myeloma2
- His translational research in multiple myeloma and chronic myeloid neoplasms is concerned with the effects of chromatin remodeling on gene expression in cancer cells. (mayo.edu)
- PDQ plasma cell neoplasms (including multiple myeloma) treatment. (medlineplus.gov)
Seroconversion3
- Several studies that evaluated antibody response to COVID-19 vaccination found that patients with solid malignancies had lower serologic response rates compared to healthy controls, but better than patients with haematologic malignancies, who had the lowest seroconversion rates and antibody titres. (ecancer.org)
- Immunogenicity outcomes of interest were seroconversion, geometric mean titers (GMTs), or antibody avidity. (cdc.gov)
- 2019). Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium. (who.int)
Inhibitors1
- TNF)-alpha inhibitors (etanercept), interleukin-1 (IL-1) blocking agents and other monoclonal antibodies targeting immune cells (e.g., rituximab, alemtuzumab, etc), etc. (who.int)
Protein7
- Total lysates (15 µg protein) from HeLa (Low expression negative control) and PC-3 (Positive control) were resolved by electrophoresis (4-20% Tris-glycine gel), transferred to nitrocellulose, and probed with 1:500 (1 µg/ml) purified anti-Nestin antibody, clone 10C2. (biolegend.com)
- Fibronectin antibody recognizes fibronectin protein, which is an extracellular glycoprotein (predicted molecular weight of 272 kDa) that exists in two forms. (genetex.com)
- Fibronectin antibody [N1N2], N-term immunoprecipitates Fibronectin protein in IP experiments. (genetex.com)
- IP Sample: HeLa whole cell lysate/extract A : 30 μg whole cell lysate/extract of Fibronectin protein expressing HeLa cells B : Control with 3 μg of pre-immune rabbit IgG C : Immunoprecipitation of Fibronectin by 3 μg of Fibronectin antibody [N1N2], N-term (GTX112794) 5% SDS-PAGE The immunoprecipitated Fibronectin protein was detected by Fibronectin antibody [N1N2], N-term (GTX112794) diluted at 1 : 1000. (genetex.com)
- Fibronectin antibody [N1N2], N-term detects FN1 protein at cytosol on human hepatoma by immunohistochemical analysis. (genetex.com)
- Fibronectin antibody detects Fibronectin protein by Western blot analysis. (genetex.com)
- Western Blot: Cyclin D1 Antibody (SPM587) [NBP2-32840] - HELLS expression and protein levels are modulated with YAP1/TEAD inhibition downstream of SHH signaling. (novusbio.com)
Immunohistochemical evaluation2
- In this manuscript, we describe the immunohistochemical evaluation of the mesothelioma TMA with three key antibodies that are used in making the diagnosis of mesothelioma, and compared the immunohistochemical assessment between manual scoring and image analysis. (cdc.gov)
- This is a unique case due to the low frequency 2 , the atypical clinical history, but mainly the difficult histopathological differential diagnosis and immunohistochemical evaluation among these neoplasms. (bvsalud.org)
Assays3
- These assays involve incubating the cells with the monoclonal antibodies or labeled derivatives thereof. (justia.com)
- DESIGN, SETTING, AND PARTICIPANTS: Four serial histologic sections from 90 archival non-small cell lung cancers from January 1, 2008, to December 31, 2010, were distributed to 3 sites that performed the following immunohistochemical assays: 28-8 antibody on the Dako Link 48 platform, 22c3 antibody on the Dako Link 48 platform, SP142 antibody on the Ventana Benchmark platform, and E1L3N antibody on the Leica Bond platform. (tamu.edu)
- A new study available on the pre-print server medRxiv* aims to assess the specificity of the serological assays of SARS-CoV-2 antibodies among patients known to have a tissue-borne parasitic infection or those who reside in areas where the virus is endemic. (news-medical.net)
Cancer7
- After adjustment for smoking and other sexually transmitted diseases, antibodies to C. trachomatis showed the strongest association with cervical cancer (odds ratio = 5.0 (95% confidence interval 1.6-15.7)), but the numbers were too small for drawing conclusions as to the sexually transmitted diseases with which cervical cancer is most specifically associated. (ox.ac.uk)
- Methods Observational study investigating patients with myeloneuropathy and underlying cancer or onconeural antibody seropositivity. (neurology.org)
- Western Blot: Cyclin D1 Antibody (SPM587) [NBP2-32840] - analysis of Cyclin D1 in human breast cancer cell line MDA-MB-231 cell lysate using anti-Cyclin D1. (novusbio.com)
- Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described. (justia.com)
- Another aspect of the invention concerns labeled derivatives of the above described monoclonal antibodies that are labeled with a detectable label that permits the derivatives to be used in diagnosing or monitoring human breast cancer. (justia.com)
- Monoclonal antibodies and cancer therapy : proceedings of the Roche-UCLA Symposium, held in Park City, Utah, January 26-February 2, 1985 / editors, Ralph A. Reisfeld, Stewart Sell. (who.int)
- This is an open label single-arm phase II study to evaluate the combination therapy of the antibody drug conjugate, sacituzumab govitecan, and the anti-PD-L1 antibody, atezolizumab, in patients with triple negative breast cancer . (survivornet.com)
Autoantibodies2
- Plasmapheresis is effective because the autoantibodies, which are most often IgM, are loosely bound to the erythrocytes, and IgM antibodies are incapable of diffusing into the extravascular space. (medscape.com)
- Another autoimmune hemolytic anemia syndrome associated with cold-reacting autoantibodies is paroxysmal cold hemoglobinuria , which involves the IgG Donath-Landsteiner (D-L) antibody. (medscape.com)
Immune5
- Statistical analyses were performed from December 1, 2015, to August 30, 2016, to compare antibodies and pathologists' scoring of tumor and immune cells. (tamu.edu)
- CONCLUSIONS AND RELEVANCE: The assay using the SP142 antibody is an outlier that detected significantly less PD-L1 expression in tumor cells and immune cells. (tamu.edu)
- The pathologists showed excellent concordance when scoring tumor cells stained with any antibody but poor concordance for scoring immune cells stained with any antibody. (tamu.edu)
- Convalescent plasma may be beneficial in COVID-19 patients with B-cell neoplasm who are unable to mount a humoral immune response. (bvsalud.org)
- NG-641 is an oncolytic adenoviral vector which expresses a FAP-TAc antibody together with an immune enhancer module (CXCL9/CXCL10/IFNα). (clinicaltrials.gov)
Tumor cells1
- The antibodies that attack the neural tissue develop in response to tumor cells. (loinc.org)
Biological1
- In addition, several biological therapies are currently available for these patients, including interferons, rituximab, and radiolabeled antibodies (the newest biological therapy). (medscape.com)
Trachomatis1
- These 32 individuals and 64 matched controls were analyzed for serum antibodies indicative of past infection with Chlamydia trachomatis, Neisseria gonorrhoeae, cytomegalovirus, Epstein-Barr virus, and herpes simplex virus type 2. (ox.ac.uk)
Mucinous1
- 1) Background: A reliable non-invasive distinction between low- and high-risk pancreatic intraductal papillary mucinous neoplasms (IPMN) is needed to effectively detect IPMN with malignant potential. (jefferson.edu)
Neuroendocrine1
- 2020). A molecular map of lung neuroendocrine neoplasms. (who.int)
Systemic1
- Zhai Y, Zhong Z, Zariffard M, Spear GT, Qiao L. Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies. (rush.edu)
Human3
- The first study investigating tissue‐specific antibodies in the human prostate can be traced back to 1969 by Ablin et al. (intechopen.com)
- Cyclin D1, one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms. (novusbio.com)
- A study of 735 hematopoietic and nonhematopoietic human neoplasms. (biocare.net)
DyLight1
- Then the cells were intracellularly stained with 2 µg/mL anti-Nestin Antibody (10C2) and followed by DyLight™ 594 goat anti-mouse IgG (red) for 1 hour at room temperature. (biolegend.com)
Serum1
- Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. (ox.ac.uk)
Peptides1
- Substituting a pyridine ring for a benzene ring in the acylation agent N-succinimidyl 3-iodobenzoate has resulted in a useful approach for the radiohalogenation of monoclonal antibodies, peptides, and labeled biotin conjugates. (duke.edu)
Malignancies2
- This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. (clinicaltrials.gov)
- He has been senior physician at Guy's Hospital since May 2018, a reader at King's College London since August 2022 and continues to study the immunobiology of Myeloid Malignancies and Neoplasms. (kcl.ac.uk)
Lesions2
- IMSEAR at SEARO: Role of HSV antibodies in precancerous & cancerous lesions of the uterine cervix--a prospective study. (who.int)
- Primary malignant neoplasms of the sweat glands are rare, constituting less than 1% of all primary malignant skin lesions 1 . (bvsalud.org)